Donald A Bergstrom Relay Therapeutics, Inc. (RLAY) insider trading activity

Donald A Bergstrom is President, R&D of Relay Therapeutics, Inc.. Currently has a direct ownership of 524,081 shares of RLAY, which is worth approximately $3.98 Million. The most recent transaction as insider was on Mar 01, 2022, when has been sold 8,000 shares (Common Stock) at a price of $4.12 per share, resulting in proceeds of $32,960. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 524K

0.63% 3M change

120.29% 12M change

Total Value Held $3.98 Million

Donald A Bergstrom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 7.21%	102,926 Common Stock
Feb 22 2022	SELL Open market or private sale	$481,724 $20.95 p/Share	22,994 Reduced 19.5%	94,926 Common Stock
Feb 22 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 6.35%	117,920 Common Stock
Jan 27 2022	BUY Grant, award, or other acquisition	-	64,950 Added 37.14%	109,920 Common Stock
Dec 27 2021	SELL Open market or private sale	$21,482 $33.1 p/Share	649 Reduced 1.42%	44,970 Common Stock
Oct 15 2021	SELL Open market or private sale	$1,024,500 $34.15 p/Share	30,000 Reduced 39.67%	45,619 Common Stock
Sep 27 2021	SELL Open market or private sale	$23,818 $36.87 p/Share	646 Reduced 0.85%	75,619 Common Stock
Jun 28 2021	SELL Open market or private sale	$34,951 $35.81 p/Share	976 Reduced 1.26%	76,265 Common Stock
Jun 16 2021	SELL Open market or private sale	$1,425,668 $33.75 p/Share	42,242 Reduced 35.35%	77,241 Common Stock
Jun 16 2021	BUY Exercise of conversion of derivative security	$174,037 $4.12 p/Share	42,242 Added 26.12%	119,483 Common Stock
Apr 16 2021	SELL Open market or private sale	$1,822,645 $32.36 p/Share	56,324 Reduced 42.17%	77,241 Common Stock
Mar 26 2021	BUY Grant, award, or other acquisition	-	34,999 Added 20.76%	133,565 Common Stock

Also insider at

FUSN

Fusion Pharmaceuticals Inc. Healthcare

DAB